publication venue for
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.. oyae219. 2024
- 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. 29:S8-S9. 2024
- 23 Pre-surgical visceral adipose tissue may be a novel pre-surgical risk factor for acute kidney injury among clear cell renal cell cancer patients undergoing radical nephrectomy. 29:S19-S20. 2024
- 35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC). 29:S22-S22. 2024
- Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. 29:699-706. 2024
- 20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study. 29:S8-S9. 2024
- 35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC). 29:S22-S22. 2024
- A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma. 29:519-526. 2024
- Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab. 28:e712-e722. 2023
- Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. 28:555-564. 2023
- Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. 27:e286-e293. 2022
- Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. 25:981-992. 2020
- Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. 25:e1509-e1515. 2020
- Evolution of Cancer Care in Response to the COVID-19 Pandemic. 25:e1426-e1427. 2020
- In Reply. 25:e1252-e1253. 2020
- Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. 25:e1091-e1097. 2020
- A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. 25:e936-e945. 2020
- In Reply. 25:E1252-E1253. 2020
- Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. 25:64-77. 2020
- The Development of an International Oncofertility Competency Framework: A Model to Increase Oncofertility Implementation. 24:e1450-e1459. 2019
- Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?. 24:1405-1409. 2019
- Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. 24:349-357. 2019
- Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. 23:768-775. 2018
- Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. 20:474-482. 2015
- Changes in Functional Performance Measures in Adults Undergoing Chemoradiation for Primary Malignant Glioma: A Feasibility Study. 15:636-647. 2010
- Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity. 12:1035-1043. 2007
- Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.. 12:1035-1043. 2007
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors. 12:426-437. 2007
- Cancer in 15- to 29-Year-Olds by Primary Site. 11:590-601. 2006
- Management of Bleeding in Patients with Advanced Cancer. 9:561-570. 2004
- Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey. 8:381-388. 2003
- Evidence for Equivalent Electrocardiographic Changes Among the 5-HT3 Receptor Antagonists. 8:216-218. 2003
- The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy. 7:481-491. 2002